Beyond Avoidance: IgE-Mediated Food Allergies – Therapeutic Innovations to the Rescue
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing education activity is jointly provided by and .
Support Statement
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Activity Description
In the United States, food-induced allergic reactions are the leading cause of anaphylaxis in hospital emergency departments. Among these, immunoglobulin E (IgE)-mediated food allergies are the most common, and they pose significant risks, including cardiac arrest and respiratory failure. Traditionally, treatment options for IgE-mediated food allergies have been primarily limited to food avoidance and anaphylaxis prevention. However, recent years have brought the FDA approval of the first oral immunotherapy agent for peanut allergy in addition to the biologic omalizumab for IGE-mediated food allergies. This educational program, developed in collaboration with Food Allergy Research & Education (FARE), aims to provide family medicine physicians and other healthcare professionals with the latest insights into managing IgE-mediated food allergies. The panel of distinguished experts will explore the pathophysiological underpinnings of IgE-mediated food allergies, assess the efficacy and safety of traditional and emerging treatments, and discuss the latest guidelines for managing these conditions. The panel will also highlight the importance of shared decision-making and interdisciplinary approaches to optimize patient care.
Target Audience
The intended audience for this activity includes family medicine physicians, primary care physicians, nurse practitioners, physician associates, and other healthcare professionals involved in the management of patients with IgE -mediated food allergies.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Evaluate the pathophysiological mechanisms that underlie the development of IgE-mediated food allergies.
- Outline the safety and efficacy of conventional, newly approved, and investigational treatments to manage IgE-mediated food allergies.
- Examine the most recent guidelines to manage IgE-mediated food allergies.
- List shared decision-making and interprofessional approaches for the improved management of patients with IgE-mediated food allergies.
Activity Chair
Robert A. Wood, MD, FAAAAI
Julie and Neil Reinhard Professor of Pediatric Allergy and Immunology
Professor of Pediatrics and International Health
Director, Eudowood Division of Pediatric Allergy, Immunology, & Rheumatology
Director, Pediatric Clinical Research Unit
Deputy Director, Institute of Clinical and Translational Research
Johns Hopkins University School of Medicine
Baltimore, MD
Faculty
Kelly Cleary, MD, FAAP
Senior Director of Education and Support Programs
Food Allergy Research and Education (FARE)
Westfield, NJ
Barbara P. Yawn, MD, MSc, FAAFP
Adjunct Professor, Department of Family and Community Health
University of Minnesota
Minneapolis, MN
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Linda A. Giarraputo, BS, PA-C
Accreditation
In support of improving patient care, this activity has been planned and implemented by Vindico Medical Education and Food Allergy Research and Education. Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Vindico Medical Education has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until August 14, 2025. PAs should only claim credit commensurate with the extent of their participation.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, August 15, 2024, to August 14, 2025.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education and Food Allergy Research and Education adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Kelly Cleary, MD, FAAP
No relevant financial relationships to disclose.
Robert A. Wood, MD, FAAAAI
Consultant: Genentech
Barbara P. Yawn, MD, MSc, FAAFP
Advisor: AstraZeneca, GSK, Teva
Consultant: AstraZeneca, Boehringer Ingelheim, GSK, Teva
Speaker Contracted by Ineligible Company: GSK
Planners/Reviewers report the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Linda A. Giarraputo, BS, PA-C
No relevant financial relationships to disclose.
Vindico Medical Education and Food Allergy Research and Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2024 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and Food Allergy Research and Education continuing education activities does not necessarily reflect the views and opinions of Vindico Medical Education or Food Allergy Research and Education. Neither Vindico Medical Education, Food Allergy Research and Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by contacting our designated copyright agent (as outlined below). In your email, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (eg, URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you are either the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614
CE Questions?
Contact us at cme@vindicoCME.com